LARAD awarded USDA Phase I SBIR Grant

Wooster, OH, April 13, 2017: LARAD, a startup using proprietary virus-like-particle (VLP) technology to develop vaccines and diagnostics for animal diseases, received a $98,000 Small Business Innovation Research (SBIR) grant to develop a VLP vaccine for chicken anemia virus. The 9 month Phase I grant from the United States Department of Agriculture (USDA) will allow LARAD to produce the chicken anemia virus VLP, which can be used as both a diagnostic reagent and a vaccine.

“Chicken anemia virus (CAV) is an important avian pathogen that causes anemia and immunodeficiency leading to secondary infections,” said Dr. Daral Jackwood, LARAD founder and chief executive officer. “And diagnosis in chicken flocks, particularly breeder flocks is very important to the control of the virus.” LARAD’s CAV VLP antigens will improve the overall quality of diagnostic tests and reduce the cost of antigen production.

Additionally, the CAV VLP can be used as a vaccine in nearly all breeder chicken flocks. This new vaccine would give poultry producers a safe and reliable product that will provide long term immunity. “Immunosuppressive diseases like CAV can result in $1-3 billion losses for the U.S. poultry industry” says Jackwood. “LARAD is grateful to receive this funding from the USDA to aid us in developing products to diagnose and prevent CAV and help producers reduce these losses.”

There are no comments.

Leave a Reply